GHK-Cu, BPC-157 and TB-500

01 · What it is

This guide covers three compounds administered together. The blend has no chemistry of its own and no literature of its own. Its components are:

GHK-Cu — glycyl-L-histidyl-L-lysine complexed with copper(II), molecular weight approximately 404 Da for the chelate. An endogenous human plasma constituent identified in 1973, whose best-established property is high-affinity binding of copper and other transition metals ^1,2.

BPC-157 — a synthetic pentadecapeptide, GEPPPGKPADDAGLV, molecular weight approximately 1,419 Da, described as a partial sequence of a protein isolated from human gastric juice ⁵.

TB-500 — a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, molecular weight approximately 889 Da calculated from its sequence, corresponding to residues 17–23 of thymosin β4 and identified by mass spectrometry in a product carrying that name ⁴.

No study has administered these three compounds together. That is not an oversight in this review; it is a bounded conclusion. Any three-way study would necessarily appear in a search for BPC-157 with TB-500 or thymosin β4, which returns nine PubMed records as of September 2026 — eight reviews and primers, and one primary study. That primary study tested two of the three, in rats, and reported that “combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone” ¹⁵.

So the only pairwise combination inside this blend that has ever been tested showed no addition, and the third component has never been combined with either of the others in any published experiment.

As of September 2026 none of the three holds a marketing authorisation as a drug in any jurisdiction.

02 · Evidence at a glance

Evidence grade

Preclinical

Studies of the three-compound blend

None

Studies of any pairwise combination within it

1 — BPC-157 with TB-500, in rats ¹⁵

Result of that study

No additional benefit over either agent alone ¹⁵

Human studies of the blend

None

Human studies of any pairwise combination

One 4-patient subgroup in an uncontrolled series ⁸

Pharmacokinetic interaction data

None, for any pair, in any species

Combination toxicology

None

Molecular targets identified

GHK-Cu: none, mechanism is metal chelation ². BPC-157: none ^12,14. TB-500: none ⁹

Human RCTs of any component

GHK-Cu: 1, negative on objective endpoints ³. BPC-157: none. TB-500: none

Approval status

None, any component, any jurisdiction

03 · Mechanism of action

Three different unresolved mechanisms

The rationale for this blend is that its components act on different parts of repair: copper delivery and matrix synthesis, angiogenesis, and cytoskeletal dynamics. Each of those descriptions is individually defensible and collectively misleading, because the confidence attached to them differs enormously.

GHK-Cu — the best-defined of the three. GHK binds Cu(II) with high affinity and circulates complexed with transition metals; in cell culture the metal complexes rather than the free peptide account for effects on adhesion and growth ². Copper is a cofactor for lysyl oxidase, which cross-links collagen and elastin. This is coordination chemistry and it is settled. What is not settled is delivery: GHK-Cu is hydrophilic and permeates the stratum corneum poorly, which is the central obstacle for topical use ¹¹.

BPC-157 — an association, not a target. The best-supported account is promotion of vessel formation in chorioallantoic membrane and tube-formation assays and accelerated blood-flow recovery in rat hind-limb ischaemia, associated with activation and upregulation of VEGFR2 ⁶. No molecular receptor for BPC-157 has been identified, and reviews describe its mechanism as inferred from downstream changes rather than demonstrated at a binding site ^12,14.

TB-500 — an inheritance that has been questioned in print. The actin-sequestering mechanism belongs to thymosin β4. Whether the acetylated heptapeptide inherits it is unresolved: a 2024 study stated that the documented functions of this sequence belong to its unacetylated form, that the biological effects of TB-500 itself have not been documented, and found significant wound-healing activity in the metabolite Ac-LKKTE rather than in the administered compound ⁹.

Why three unresolved mechanisms do not combine into one strong rationale

Complementarity requires that each agent produce an effect and that the effects operate through routes which do not saturate the same downstream step. For this blend, the first condition is unestablished for two of three components: BPC-157’s effects did not reach statistical significance in the one experiment that tested it head to head against TB-500 ¹⁵, and TB-500’s own activity was absent in the only assay that tested it directly ⁹. Adding a third agent to two whose individual contributions are uncertain does not strengthen the rationale. It makes any observed result harder to attribute, not easier.

There is also a mechanistic tension nobody has examined. If BPC-157 acts through VEGFR2 upregulation ⁶ and GHK-Cu supports angiogenesis and matrix remodelling ^1,7, both are pushing the same downstream process — the situation in which additivity is least likely and in which the single pairwise test that exists already failed to find it ¹⁵.

04 · Key research findings

The blend itself. No study. No in vitro work, no animal work, no human data, no case reports. The three-way combination has never been administered in a published experiment.

The one pairwise test inside the blend. Thirty-two rats underwent Achilles tendon transection and repair and were randomised to control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both, intraperitoneally for four weeks. Maximum load to failure exceeded control in both single-agent groups, reaching significance only for TB-500; total Bonar scores were significantly lower than control in the TB-500 group (p = 0.016); total Movin scores were significantly lower in the TB-500 group (p = 0.017) and the combination group (p = 0.040); and the combination conferred no additional benefit over either agent alone ¹⁵.

Eight animals per arm, one dose level of each, four weeks — a null combination result that does not exclude a small effect but does not support one either.

The one human observation involving two components. In a retrospective chart review at a single clinic, seventeen patients received intra-articular peptide injection for knee pain; sixteen were reached by telephone. Twelve received BPC-157 alone, of whom eleven (91.6%) reported significant improvement; four received BPC-157 with thymosin β4, of whom three (75%) reported improvement. No imaging, no control group, no validated instrument ⁸.

A four-patient subgroup whose response rate was numerically lower than the single-agent group in the same series.

Component evidence, stated at its true weight. GHK-Cu: one indexed randomised controlled trial on human skin, thirteen completers, negative on erythema, wrinkles and skin quality by objective and blinded assessment, positive only on a patient questionnaire ³. BPC-157: no randomised controlled trial indexed for any indication; twenty-nine human subjects across two uncontrolled case series from one clinic ^8,10. TB-500: no human data of any kind, and its parent compound’s clinical record belongs to a different molecule ^4,9.

Summed, three components contribute one small negative randomised trial and twenty-nine uncontrolled human subjects.

Independent assessment of the components. Reviews written for orthopaedic and sports medicine audiences list BPC-157, TB-500 and GHK-Cu together among peptides with mechanistic rationale and unvalidated clinical benefit, and none identifies combination evidence for any pairing ^12,13,16,17.

Where independent reviewers have looked at these compounds as a group, they have found the same absence this guide reports.

05 · Evidence overview

06 · Safety profile

Animal data. No combination toxicology exists for any pair or for the triple. For the components individually: this review identified no repeat-dose toxicology, genotoxicity, reproductive or carcinogenicity study for BPC-157 in the indexed literature; none of any kind for TB-500; and no systematic toxicology programme for GHK-Cu. The single pairwise animal study did not report systemic toxicity outcomes for any arm ¹⁵. The 2024 metabolite study found no cytotoxicity of TB-500 or its metabolites in fibroblasts, which is one cell type and acute exposure ⁹.

Human data. None for the blend. The four-patient subgroup that received two of the three components was assessed by telephone survey months after injection, a method not designed to capture adverse events ⁸.

What is genuinely unknown, and what a three-way blend adds. Everything unknown about each component applies here. Combination adds two problems specific to this guide.

The first is attribution. When three uncharacterised preparations are administered together, no observation — beneficial or adverse — can be assigned to any of them, to an interaction, or to none. This is not a theoretical objection; it is why the four-patient human subgroup is uninterpretable ⁸, and why the FDA-adjacent literature on peptide products repeatedly notes that multi-ingredient use complicates causal assessment.

The second is copper. GHK-Cu delivers copper, and no published work quantifies systemic copper exposure from injected GHK-Cu at any dose ². Adding two further peptides to an unquantified metal load does not change that gap; it obscures it further. No study has examined whether copper availability interacts with the angiogenic signalling attributed to BPC-157 ⁶, though copper is itself an established participant in angiogenesis — which makes this the most obvious untested interaction in the blend.

Also unknown: whether the three compounds are chemically compatible in a shared vehicle, whether co-formulation alters aggregation or degradation, and what a mixed preparation actually contains. Peptide-related impurities, aggregation and difficulty characterising the active ingredient are documented problems for BPC-157 alone ¹⁴; TB-500 adsorbs substantially to labware, affecting recovery in quantitative work ⁹. Nobody has characterised a three-component mixture.

07 · US regulatory status

Current as of 6 September 2026. None of the three compounds is approved as a drug in the United States or any other jurisdiction, and none is a controlled substance. No combination product containing any two or three of them has been evaluated by any regulator.

All three were placed in category 2 of FDA’s interim bulk drug substances policy in September 2023 — BPC-157; “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”; and GHK-Cu for injectable routes of administration. As of FDA’s page dated 22 April 2026 all three entries appear in the table of substances nominated but subsequently withdrawn by the nominators ¹⁸. BPC-157 and TB-500 were reviewed individually by FDA’s Pharmacy Compounding Advisory Committee on 23 July 2026, for ulcerative colitis and wound healing respectively; GHK-Cu was not on that agenda, and no combination was ¹⁹. Advisory committee recommendations are non-binding and nothing has been added to the 503A Bulks List as a result.

GHK-Cu is separately used as a cosmetic ingredient, a different regulatory pathway that does not extend to injectable use or to combination with other peptides.

Under the World Anti-Doping Code, growth factors affecting muscle, tendon or ligament regeneration are prohibited at all times, and substances not approved by any governmental regulatory health authority for human therapeutic use fall within category S0.

08 · Limitations of the evidence

1. There is no evidence for this blend. Not weak evidence, not preliminary evidence — no study has administered these three compounds together. Every statement made about the combination anywhere is an extrapolation from components.
2. The only pairwise test within the blend was null. BPC-157 with TB-500 conferred no additional benefit over either agent alone in the single experiment designed to detect it ¹⁵. That is the nearest thing to direct evidence this blend has, and it does not support combining.
3. Component evidence cannot be added. Pharmacology does not permit summing results across separate studies. Two of the three components have no randomised human evidence at all, and the third has one small randomised trial that was negative on every objective endpoint ³.
4. Attribution is structurally impossible. Any effect from a three-component preparation belongs to an unknown. This limitation cannot be designed around except by studying the agents separately first, which for TB-500 has essentially not been done ⁹ and for injected GHK-Cu has not been done at all.
5. The copper load is unquantified. GHK-Cu is a copper carrier ², no study measures systemic copper exposure from injected administration, and copper participates in the same angiogenic processes attributed to another component of the blend ⁶. That is an untested interaction sitting at the centre of the rationale.
6. Nothing is known about the mixture as a physical preparation. No compatibility, stability, aggregation or content-uniformity data exist for any combination of these three peptides, and characterisation problems are documented for the components individually ^9,14.
7. The blend originated outside the literature. No published scientific rationale predates it. It was assembled first and has not been tested since, which is the reverse of how combination therapy is normally established.

09 · References

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85–87.

   PMID 4349963 ↗

2. Pickart L, Thaler MM. Growth-modulating tripeptide (glycylhistidyllysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol. 1980;102(2):129–139.

   PMID 6246126 ↗

3. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252–259.

   PMID 16847171 ↗

4. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733–738.

   PMID 22962027 ↗

5. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126–1135.

   PMID 23755725 ↗

6. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333.

   PMID 27847966 ↗

7. Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2017;25(2):270–278.

   PMID 28370978 ↗

8. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13.

   PMID 34324435 ↗

9. Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033.

   PMID 38382158 ↗

10. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–17.

    PMID 39325560 ↗

11. Ogórek K, Nowak K, Wadych E, Ruzik L, Timerbaev AR, Matczuk M. Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes? Molecules. 2025;30(1):136.

    PMID 39795193 ↗

12. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495.

    PMID 40756949 ↗

13. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223–229.

    PMID 41476424 ↗

14. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625.

    PMID 42198317 ↗

15. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822–837.

    PMID 42542926 ↗

16. Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236.

    PMID 41490200 ↗

17. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026; online ahead of print.

    PMID 42578445 ↗

18. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current as of 22 April 2026. Regulatory document; no PMID.

    Source ↗

19. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. Regulatory document; no PMID.

    Source ↗